🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
542,50 USD
Máx. histórico
558,88
6 días
Split 2:1 del 24/08/2000
Caída desde máximo
-2,93%
Rango 52 semanas
406,67 – 568,67
Variación hoy
-1,19%
Cierre anterior
549,04
Rango de hoy
540,02 – 557,85
Volumen hoy
2.467.517
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 34,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 23 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 10/11/2010 | 34,30 | 34,77 | 34,24 | 34,44 | +0,50% | 1,55% | 1.942.300 |
| 09/11/2010 | 34,57 | 34,62 | 34,05 | 34,27 | -0,70% | 1,65% | 2.372.400 |
| 08/11/2010 | 34,88 | 35,00 | 34,15 | 34,51 | -1,57% | 2,44% | 2.070.100 |
| 05/11/2010 | 34,71 | 35,14 | 33,83 | 35,06 | +0,83% | 3,77% | 4.505.200 |
| 04/11/2010 | 36,98 | 37,19 | 34,69 | 34,77 | -5,21% | 6,76% | 4.333.400 |
| 03/11/2010 | 37,18 | 37,37 | 36,35 | 36,68 | -1,61% | 2,74% | 2.040.000 |
| 02/11/2010 | 38,17 | 38,25 | 37,12 | 37,28 | -1,77% | 2,96% | 2.929.600 |
| 01/11/2010 | 38,58 | 38,70 | 37,64 | 37,95 | -0,91% | 2,75% | 2.298.300 |
| 29/10/2010 | 38,09 | 38,48 | 37,94 | 38,30 | +0,00% | 1,42% | 1.621.300 |
| 28/10/2010 | 38,50 | 38,50 | 38,00 | 38,30 | -0,13% | 1,30% | 2.220.900 |
| 27/10/2010 | 37,06 | 38,37 | 36,85 | 38,35 | +2,05% | 4,10% | 2.260.700 |
| 26/10/2010 | 36,89 | 37,75 | 36,46 | 37,58 | +0,70% | 3,50% | 2.556.500 |
| 25/10/2010 | 36,73 | 37,45 | 36,73 | 37,32 | +2,44% | 1,96% | 2.035.400 |
| 22/10/2010 | 36,00 | 36,46 | 35,72 | 36,43 | +1,62% | 2,06% | 1.389.100 |
| 21/10/2010 | 36,63 | 36,64 | 35,50 | 35,85 | -1,89% | 3,11% | 1.416.000 |
| 20/10/2010 | 37,24 | 37,24 | 36,46 | 36,54 | -1,40% | 2,09% | 1.460.500 |
| 19/10/2010 | 36,60 | 37,16 | 36,32 | 37,06 | +0,46% | 2,30% | 3.010.300 |
| 18/10/2010 | 35,98 | 36,90 | 35,89 | 36,89 | +2,39% | 2,81% | 1.949.000 |
| 15/10/2010 | 34,93 | 36,21 | 34,87 | 36,03 | +3,18% | 3,84% | 2.288.900 |
| 14/10/2010 | 34,84 | 34,97 | 34,31 | 34,92 | +1,81% | 1,89% | 2.402.000 |
| 13/10/2010 | 34,87 | 35,00 | 34,30 | 34,30 | +0,00% | 2,01% | 2.352.400 |
| 12/10/2010 | 34,75 | 34,75 | 34,11 | 34,30 | -1,80% | 1,84% | 1.835.800 |
| 11/10/2010 | 35,05 | 35,06 | 34,68 | 34,93 | -1,08% | 1,08% | 958.800 |
| 08/10/2010 | 35,11 | 35,41 | 34,50 | 35,31 | +0,54% | 2,59% | 1.533.100 |
| 07/10/2010 | 34,66 | 35,18 | 34,06 | 35,12 | +2,51% | 3,23% | 1.808.400 |
| 06/10/2010 | 34,63 | 34,83 | 34,16 | 34,26 | -1,32% | 1,93% | 1.355.600 |
| 05/10/2010 | 34,43 | 34,79 | 34,27 | 34,72 | +2,27% | 1,51% | 1.725.000 |
| 04/10/2010 | 34,33 | 34,76 | 33,78 | 33,95 | -1,37% | 2,85% | 1.177.600 |
| 01/10/2010 | 35,01 | 35,08 | 33,98 | 34,42 | -0,43% | 3,14% | 1.711.600 |
| 30/09/2010 | 35,30 | 35,52 | 34,51 | 34,57 | -1,06% | 2,86% | 1.909.400 |